Updates are available Correction dated 2025-11-18
Click to view Correction: https://doi.org/10.1007/s10689-025-00510-7
-
Authors
de Jong, Chiem L https://orcid.org/0009-0008-1630-905X
Schijven, Gina
Engelhardt, Ellen G https://orcid.org/0000-0003-0016-4972
Jager, Agnes https://orcid.org/0000-0002-7713-1450
Ausems, Margreet G. E. M. https://orcid.org/0000-0003-0305-3477
-
Funding
Funding for this research was provided by:
AstraZeneca (aznl202300195)
- License Information
-
More Information
Article History
Received: 23 June 2025
Accepted: 21 September 2025
First Online: 14 October 2025
Change Date: 18 November 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10689-025-00510-7
Declarations
:
: CLdJ, GS and AJ and EGE declare that they have no conflicts of interest. MGEMA received consulting fees from AstraZeneca for participation in an international Steering Committee to give advice on a Train-The-Trainer programme and a honorarium for a lecture on genetic testing in breast cancer. These payments were made to the institution (University Medical Center Utrecht).
: Written informed consent was obtained from all participants. Participants were told that participation was voluntary and that the results of the interviews would be anonymised before publication. This study does not fall under the scope of the Dutch Medical Research Involving Human Subjects Act (WMO). It therefore does not require approval from an accredited medical ethics committee in the Netherlands. However, an independent quality check has been carried at UMC Utrecht out to ensure compliance with legislation and regulations, as well as looking at informed consent procedure, data management, privacy aspects and legal aspects.
